Oocyte donation outcome after oncological treatment in cancer survivors

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Fernandez I
  • Martinez M
  • Tocino A
  • Portela S
  • García-Velasco JA

Grupos

Abstract

Objective: To study reproductive outcome in patients cured of cancer who required oocyte donation (OD) owing to iatrogenic ovarian dysfunction. Design: Multicenter, unmatched, retrospective cohorts study. Setting: Private, university-affiliated group of clinics. Patient(s): Women treated and cured of cancer (n = 142) who underwent 333 cycles of OD (exposed group) and women without a previous cancer diagnosis (n = 17,844) who underwent 29,778 cycles of OD (unexposed cohort) between January 2000 and January 2012. Intervention(s): Retrospective chart review. Main Outcome Measure(s): Pregnancy, implantation, miscarriage, and ongoing pregnancy rates. Result(s): There were no differences in terms of pregnancy (55.7% vs. 54.7%), implantation (39.8% vs. 38.2%), miscarriage (29.5% vs. 26.9%), or delivery rates (39.3% vs. 39.9%) between the unexposed group and the patients previously diagnosed and cured of cancer, respectively. There was no correlation between OD outcome and cancer type. Conclusion(s): Endometrial receptivity in women treated and cured of cancer was comparable to that of general patients without previous malignancies who had received OD, based on the largest series available in the literature. (C) 2015 by American Society for Reproductive Medicine.

Datos de la publicación

ISSN/ISSNe:
0015-0282, 1556-5653

FERTILITY AND STERILITY  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
205-213
Factor de Impacto:
2,278 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Assisted reproduction; cancer; chemotherapy; oocytes donation; radiotherapy

Campos de estudio

Proyectos asociados

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL

CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

CONTRATO POST FSE (RIO HORTEGA)

CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.

Investigador Principal: VICENTE PAYÁ AMATE

M12-671

Cita

Compartir